- Reuters•3 days ago
Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market. Investors had been making space for the well-telegraphed deal ever since Teva announced its US$40.5bn acquisition of Allergan Generics earlier in the year, while declining rates across the developed world and a lack of recent supply in the US and European markets added impetus to the transaction. In Europe, Teva issued bonds that priced up to 35bp inside its secondary curve - and those outstanding bonds, in turn, tightened by an incredible 40bp during the execution process.
- Bloomberg•4 days ago
Teva Pharmaceutical Industries Ltd. sold Swiss-franc denominated bonds and said it had raised enough money in a sweep of markets worldwide to close a $40.5 billion acquisition.
Teva Pharmaceutical Industries LimitedTel Aviv
|Bid||21,010.00 x 200|
|Ask||21,020.00 x 34100|
|52wk Range||189.40 - 21,080.00|
|Day's Range||21,010.00 - 21,080.00|
|Avg Vol (3m)||497,807|
As of 9:24 AM EDT. Market closed.